Checkpoint Trends Ltd

Checkpoint Trends Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential shift towards a bearish trend, raising concerns about the stock's medium to long-term momentum despite its recent volatile performance.

Checkpoint Trends Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 10 April 2026. This change reflects a combination of improved technical indicators, robust financial performance, attractive valuation metrics, and a positive quality assessment, signalling a cautious but optimistic outlook for investors.

Checkpoint Trends Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 6 April 2026. This shift reflects a nuanced reassessment across four key parameters: quality, valuation, financial trend, and technicals, highlighting both strengths and emerging concerns in the company’s outlook.

Checkpoint Trends Ltd has witnessed a significant shift in its valuation parameters, moving from an attractive to a very attractive rating, driven by improved price-to-earnings and price-to-book value metrics. This change comes amid a challenging market backdrop where the stock has underperformed the Sensex in the short term but continues to deliver exceptional long-term returns, prompting a reassessment of its price attractiveness relative to peers in the Pharmaceuticals & Biotechnology sector.

Checkpoint Trends Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 September 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Checkpoint Trends Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 September 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 10 February 2026, providing investors with the latest insights into its performance and outlook.

Checkpoint Trends Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 04 September 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 30 January 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and technical outlook.

Checkpoint Trends Limited (formerly Rubra Medicaments Ltd.), a micro-cap pharmaceutical company with a market capitalisation of ₹66.00 crores, reported a net profit of ₹0.57 crores for Q3 FY26, marking a decline of 56.82% quarter-on-quarter but a turnaround from losses recorded in the corresponding quarter last year. The company's stock, trading at ₹123.95, has surged 1089.54% over the past year, reflecting extraordinary investor enthusiasm despite fundamental concerns about profitability and business model sustainability.

Checkpoint Trends Ltd is rated 'Hold' by MarketsMOJO. This rating was last updated on 04 Sep 2025, reflecting a shift from a previous 'Sell' stance. However, the analysis and financial metrics discussed here represent the stock's current position as of 19 January 2026, providing investors with an up-to-date view of its performance and prospects.

Checkpoint Trends Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 04 September 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 January 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Checkpoint Trends Ltd, a key player in the Pharmaceuticals & Biotechnology sector, reached a significant milestone on 7 Jan 2026 by hitting a new 52-week and all-time high of Rs.144.4. This achievement marks a continuation of the stock’s robust momentum, reflecting strong market performance over the past year.

Checkpoint Trends Ltd, a key player in the Pharmaceuticals & Biotechnology sector, reached a new all-time high of Rs.144.4 on 7 January 2026, reflecting a sustained period of robust gains and strong market performance.

Checkpoint Trends Ltd, a key player in the Pharmaceuticals & Biotechnology sector, reached a significant milestone on 6 Jan 2026 by hitting a new 52-week and all-time high of Rs.138.75. This marks a remarkable surge in the stock’s value, reflecting strong momentum over the past several weeks.

Checkpoint Trends Ltd, a key player in the Pharmaceuticals & Biotechnology sector, reached a new all-time high of Rs.138.75 on 6 Jan 2026, marking a significant milestone in its market journey. The stock’s robust performance over recent months has propelled it well above its previous benchmarks, reflecting sustained investor confidence and strong market momentum.

Checkpoint Trends Ltd, a key player in the Pharmaceuticals & Biotechnology sector, reached a significant milestone on 5 Jan 2026 by hitting a new 52-week and all-time high of Rs.132.15. This achievement marks a continuation of the stock’s robust momentum, reflecting a remarkable rally over recent weeks.

Checkpoint Trends Ltd, a key player in the Pharmaceuticals & Biotechnology sector, reached a significant milestone today by hitting an all-time high of Rs.132.15. This achievement marks a continuation of the stock’s robust upward trajectory, reflecting sustained strong performance over recent months and years.